ARS Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
SPRY$3.57+13.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $7,998 | $(54,365) |
| Non-cash adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||
| Stock-based compensation expense | 14,534 | 9,235 |
| Depreciation | 79 | 73 |
| Amortization and accretion, net | (7,254) | (6,848) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (8,175) | — |
| Inventories | (5,945) | — |
| Prepaid and other assets | (6,191) | (1,435) |
| Accounts payable and accrued liabilities (including related party amounts of $478 and $162, respectively) | 16,432 | (2,777) |
| Operating right-of-use assets and lease liabilities, net | (19) | (12) |
| Contract liability | 2,089 | (3,137) |
| Net cash provided by (used in) operating activities | 13,548 | (59,266) |
| Cash flows from investing activities: | ||
| Purchases of short-term investments, available-for-sale | (356,038) | (272,005) |
| Maturities of short-term investments, available-for-sale | 258,000 | 185,000 |
| Payments of milestone obligations under license agreements | (7,500) | — |
| Purchase of property and equipment | (563) | (175) |
| Net cash used in investing activities | (106,101) | (87,180) |
| Cash flows from financing activities: | ||
| Financing liability | 69,383 | — |
| Proceeds from exercise of common stock options and employee stock purchase plan | 3,016 | 6,899 |
| Net cash provided by financing activities | 72,399 | 6,899 |
| Net change in cash and cash equivalents | (20,154) | (139,547) |
| Cash and cash equivalents at beginning of period | 70,971 | 210,518 |
| Cash and cash equivalents at end of period | $50,817 | $70,971 |
| Supplemental cash flow information: | ||
| Removal of retrospective insurance policy acquired in the Merger, included in prepaid and other current assets and other assets, and related reduction in additional paid in capital | $— | $3,649 |
| Stock-based compensation capitalized into inventory | $319 | $— |
| Purchases of inventories included in accounts payable | $4,255 | $— |
| Purchases of property and equipment reclassed from prepaid expenses and other current assets | $— | $174 |
Notes to Consolidated Financial Statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.